eft ventricular (LV) distension during femoral venoarterial extracorporeal membrane oxygenation (VA-ECMO) support is an untoward complication, leading to pulmonary edema, insufficient myocardial recovery, and LV thrombosis.
L
eft ventricular (LV) distension during femoral venoarterial extracorporeal membrane oxygenation (VA-ECMO) support is an untoward complication, leading to pulmonary edema, insufficient myocardial recovery, and LV thrombosis. 1 Impella (Abiomed, Danvers, MA) has been reported to effectively decompress such a distended LV with minimal invasion. 2 However, we encountered a rare case who developed a huge thrombus in the descending aorta resulting from the stagnation of blood flow because of interaction between antegrade (Impella) and retrograde (VA-ECMO) flows despite adequate anticoagulation.
CASE REPORT
A 67-year-old man with history of hypertension, hyperlipidemia, diabetes mellitus, and chronic tobacco use presented to an outside hospital with chest pain and orthopnea. He was in a shock state, and his ECG showed ST elevations in the anterior leads. Emergent left heart catheter revealed total occlusion of proximal left anterior descending artery. He got intubated and was placed on an intra-aortic balloon pumping via right femoral artery. Thrombus extraction followed by coronary stenting was performed, but ultimately only thrombolysis in myocardial infarction grade 1 flow was obtained. Right heart catheter demonstrated central venous pressure of 21 mm Hg and wedge pressure of 35 mm Hg. His peak troponin T was 21.5 ng/mL, and global ejection fraction was only 10%. On the same day, he was transferred to our institution with significant amount of pressors and borderline oxygenation.
We urgently put him on VA-ECMO via left femoral arterial and venous cannulations (day 0). Because his pulsatility was minimal, intra-aortic balloon pumping inserted from the right groin was replaced by Impella CP to decompress the LV. Systemic anticoagulation with activated partial thromboplastin time of 80 seconds and antiplatelet therapy were started immediately. VA-ECMO was flowing 3.0 L per minute, and Impella was flowing 2.0 L per minute. At day 2, we decided to move on to a temporary LV assist device implantation. However, transesophageal echocardiogram at an operating room before the procedure revealed a mobile huge thrombus in the descending aorta (Figure 1 ; Movie I in the Data Supplement). Furthermore, there was a prominent blood stagnation in the entire thoracic aorta (Figure 2 ; Movie II in the Data Supplement). Procedure was aborted given significant risk of embolism after pulling out the Impella, and we observed him with systemic anticoagulation. Heparin-induced thrombocytopenia test was negative. Fortunately, his cardiac function gradually recovered, and he eventually weaned off from VA-ECMO on day 11. At day 14, repeated transesophageal echocardiogram showed a smaller thrombus with no evidence of blood stagnation in the descending aorta (Figure 3) . Subsequently, the Impella device was percutaneously removed without any sign of embolization.
DISCUSSION
We herein reported a rare case of the floating thrombus in the descending aorta after femoral VA-ECMO with Impella for cardiogenic shock despite adequate anticoagulation.
The role of VA-ECMO has rapidly increased for treatment of cardiogenic shock. Femoral VA-ECMO is the most common configuration because cannulation is quick and relatively safe. LV distension during VA-ECMO is increasingly recognized, and one of the solutions is the combined use of Impella as an LV vent. 2 In our case, this configuration enabled the patient to obtain eventual myocardial recovery; however, unexpected thrombus formation occurred. There are some speculations for this clot formation in this specific circumstance. One is the blood stagnation because of interaction between antegrade (Impella) and retrograde (VA-ECMO) flows. Depending on the flow ratio, such thrombus formation can occur anywhere throughout the entire aorta. Another thing is a coagulation state. In this patient, the thrombus arose despite adequate anticoagulation and concomitant antiplatelet therapy. It is known that coagulation factors play a great role in acute coronary syndrome, and these factors generally come back to baseline quickly after successful percutaneous coronary intervention. 3 From this perspective, we were only able to get thrombolysis in myocardial infarction grade 1 flow after coronary stenting, and this partial revasculization might have lead to persistent hypercoagulability to create the clots. Besides, anticoagulant consumption because of cardiogenic shock followed by shock liver could also result in such a hypercoagulable state. 4 It is noteworthy that the actual time lag between Impella insertion and transesophageal echocardiogram shown in Figure 1 was <30 hours, indicating that the clots were created within a short time period. Such an abrupt clot presentation would suggest an earlier surgical intervention to convert from femoral VA-ECMO and Impella device to other configurations to restore physiological antegrade flow, especially when the pathogenesis is acute myocardial infarction that could be associated with hypercoagulability.
CONCLUSIONS
A simultaneous support by femoral VA-ECMO and Impella device can create a thrombus in the descending aorta because of blood stasis within a short time period, even with appropriate anticoagulation therapy. If necessary, earlier conversion to more advanced configuration with physiological antegrade flow would be recommended.
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